Tuesday, November, 12, 2019 01:35:42

Category: Pharmaceuticals

GeoVax, Leidos to develop malaria vaccines under extended partnership

As a part of an expanded collaboration, GeoVax Labs Inc., an American biotechnology company and Leidos Inc., a scientific research company, have reportedly announced the development of malaria vaccine candidates. The USAID (United States Agency for International Development) MVDP (Malaria Vaccine Development Program) is reported …

U.S. FDA grants Fast Track designation for Iovance’s LN-145 therapy

With the Fast Track designation, Iovance is likely to increase the frequency of its communication with the U.S. FDA. Reputed biotechnology company Iovance Biotherapeutics, Inc., has reportedly been granted the Fast Track designation for its adoptive cell therapy LN-145, developed using its proprietary TIL manufacturing …

AusCann signs deal with MediPharm Labs to purchase cannabis resin

The latest move underlines MediPharm’s first international export deal. AusCann Group Holdings Ltd. (AC8), an Australian cannabis medicine company, has reportedly entered into a supply agreement with the leading cannabis extractor in Canada, MediPharm Labs Corp., for the purchase of cannabis resin. AusCann, for the …

Reata announces positive results from bardoxolone phase 2 study

The study specifies the possibility of preventing or delaying kidney failure and the need for dialysis or a kidney transplant in patients with rare chronic kidney disease. U.S. clinical-stage biopharmaceutical firm, Reata Pharmaceuticals, Inc. has recently announced its final, positive result from the focal segmental …

FDA permits Priority Review for Roche’s drug Polatuzumab Vedotin

The FDA will decide on the definitive approval by the 19th of August 2019. The U.S. Food & Drug Administration (FDA) has reportedly accepted the BLA (Biologics License Application) submitted by the Swiss multinational healthcare company, Roche. The company has been officially granted Priority Review …

Innovent, Chipscreen Biosciences team up on colorectal cancer therapy

Shenzhen Chipscreen Biosciences Ltd., a leading China-based integrated biotech company, has reportedly entered into a collaboration agreement with Innovent Biologics Inc., a Chinese development-stage biopharmaceutical company, in a major effort to evaluate the tolerability and safety of the combination therapy involving Innovent’s Sintilimab and Chipscreen’s …